Literature DB >> 25055123

PDK1: a new therapeutic target for glioblastoma?

Kiran Kumar Velpula1, Andrew J Tsung.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25055123      PMCID： PMC6124368          DOI： 10.2217/cns.14.13

Source DB:  PubMed          Journal:  CNS Oncol        ISSN： 2045-0907


× No keyword cloud information.
  14 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

3.  Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism.

Authors:  Taro Hitosugi; Jun Fan; Tae-Wook Chung; Katherine Lythgoe; Xu Wang; Jianxin Xie; Qingyuan Ge; Ting-Lei Gu; Roberto D Polakiewicz; Johannes L Roesel; Georgia Z Chen; Titus J Boggon; Sagar Lonial; Haian Fu; Fadlo R Khuri; Sumin Kang; Jing Chen
Journal:  Mol Cell       Date:  2011-12-23       Impact factor: 17.970

4.  Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC).

Authors:  Daniel Baumunk; Uta Reichelt; Jannis Hildebrandt; Hans Krause; Jan Ebbing; Hannes Cash; Kurt Miller; Martin Schostak; Steffen Weikert
Journal:  World J Urol       Date:  2012-04-29       Impact factor: 4.226

5.  A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence.

Authors:  Joanna Kaplon; Liang Zheng; Katrin Meissl; Barbara Chaneton; Vitaly A Selivanov; Gillian Mackay; Sjoerd H van der Burg; Elizabeth M E Verdegaal; Marta Cascante; Tomer Shlomi; Eyal Gottlieb; Daniel S Peeper
Journal:  Nature       Date:  2013-05-19       Impact factor: 49.962

6.  Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells.

Authors:  Thomas McFate; Ahmed Mohyeldin; Huasheng Lu; Jay Thakar; Jeremy Henriques; Nader D Halim; Hong Wu; Michael J Schell; Tsz Mon Tsang; Orla Teahan; Shaoyu Zhou; Joseph A Califano; Nam Ho Jeoung; Robert A Harris; Ajay Verma
Journal:  J Biol Chem       Date:  2008-06-09       Impact factor: 5.157

7.  Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect.

Authors:  Kiran Kumar Velpula; Arnima Bhasin; Swapna Asuthkar; Andrew J Tsung
Journal:  Cancer Res       Date:  2013-10-22       Impact factor: 12.701

8.  HIF1α modulates cell fate reprogramming through early glycolytic shift and upregulation of PDK1-3 and PKM2.

Authors:  Alessandro Prigione; Nadine Rohwer; Sheila Hoffmann; Barbara Mlody; Katharina Drews; Raul Bukowiecki; Katharina Blümlein; Erich E Wanker; Markus Ralser; Thorsten Cramer; James Adjaye
Journal:  Stem Cells       Date:  2014-02       Impact factor: 6.277

9.  Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis.

Authors:  Rosa Ferriero; Giuseppe Manco; Eleonora Lamantea; Edoardo Nusco; Maria I Ferrante; Paolo Sordino; Peter W Stacpoole; Brendan Lee; Massimo Zeviani; Nicola Brunetti-Pierri
Journal:  Sci Transl Med       Date:  2013-03-06       Impact factor: 17.956

10.  PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer.

Authors:  S M Wigfield; S C Winter; A Giatromanolaki; J Taylor; M L Koukourakis; A L Harris
Journal:  Br J Cancer       Date:  2008-06-10       Impact factor: 7.640
View more
  6 in total

1.  PDK1 governs thromboxane generation and thrombosis in platelets by regulating activation of Raf1 in the MAPK pathway.

Authors:  B K Manne; P Münzer; R Badolia; B Walker-Allgaier; R A Campbell; E Middleton; A S Weyrich; S P Kunapuli; O Borst; M T Rondina
Journal:  J Thromb Haemost       Date:  2018-05-08       Impact factor: 5.824

2.  Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival.

Authors:  Yuting Lu; Yongzhao Shao
Journal:  Cancer Drug Resist       Date:  2022-06-02

Review 3.  Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?

Authors:  Juliana B Vilar; Markus Christmann; Maja T Tomicic
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

4.  Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancers.

Authors:  Yali Zhong; Xiaoli Li; Yasai Ji; Xiaoran Li; Yaqing Li; Dandan Yu; Yuan Yuan; Jian Liu; Huixiang Li; Mingzhi Zhang; Zhenyu Ji; Dandan Fan; Jianguo Wen; Mariusz Adam Goscinski; Long Yuan; Bin Hao; Jahn M Nesland; Zhenhe Suo
Journal:  Oncotarget       Date:  2017-02-21

5.  The Signaling Pathways Controlling the Efficacy of Glioblastoma Therapy.

Authors:  N S Vasileva; A B Ageenko; V A Richter; E V Kuligina
Journal:  Acta Naturae       Date:  2022 Apr-Jun       Impact factor: 2.204

6.  Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review.

Authors:  Neha Singh; Alexandra Miner; Lauren Hennis; Sandeep Mittal
Journal:  Cancer Drug Resist       Date:  2021-03-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.